Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up
NCT ID: NCT03172195
Last Updated: 2025-06-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
80 participants
INTERVENTIONAL
2017-10-11
2024-05-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence of Cytomegalovirus Infection in Patients With Quiescent Ulcerative Colitis
NCT02684734
QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis
NCT04030676
Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel Disease
NCT00222378
Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy
NCT04064697
RCT: HDWL vs Virtual Chromoendoscopy in the Detection of Intraepithelial Neoplasia in Longstanding Colitis
NCT02822352
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with ulcerative colitis
Patients with ulcerative colitis will have a rectosigmoidoscopy, biopsies and blood sample.
rectosigmoidoscopy
A rectosigmoidoscopy will be realized and two fragments will be collected.
biopsies
For this study, two biopsies in healthy area and two biopsies in ulcer will be collected.
blood sample
Blood sample will be collected in more.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rectosigmoidoscopy
A rectosigmoidoscopy will be realized and two fragments will be collected.
biopsies
For this study, two biopsies in healthy area and two biopsies in ulcer will be collected.
blood sample
Blood sample will be collected in more.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Voluntary to participate to the study
* Flare-up of ulcerative colitis with Mayo score \>6
* Ability to receive steroid or anti-TNF therapy
* Agree the rectosigmoidoscopy and the therapies
Exclusion Criteria
* Pregnancy
* Disagree the rectosigmoidoscopy or the therapies
* Participation to the evaluation of a new therapy
* Colectomy (partial or total)
* Contraindication of steroid or anti-TNF therapy
* Anticoagulant drugs
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Saint Etienne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xavier Roblin, MD PhD
Role: PRINCIPAL_INVESTIGATOR
CHU SAINT-ETIENNE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Saint-Etienne
Saint-Etienne, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANSM
Identifier Type: OTHER
Identifier Source: secondary_id
1708033
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.